memantine has been researched along with Absence Seizure in 34 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We found that intracisternal injection of amiloride, an acid-sensing ion channel blocker, dose-dependently reduced cerebral hypoxia-induced neurodegeneration, seizures, and audiogenic myoclonic jerks." | 7.79 | Amiloride but not memantine reduces neurodegeneration, seizures and myoclonic jerks in rats with cardiac arrest-induced global cerebral hypoxia and reperfusion. ( Tai, KK; Truong, DD, 2013) |
| "Intramuscular injection of selective NMDA receptor antagonists memantine and arcaine 4-fold decreased the incidence of pentylenetetrazole-induced generalized tonic-clonic seizures in rats, while the incidence of clonic seizures decreased by 1." | 7.74 | Combined blockade of AMPA and NMDA receptors in the brain of rats prevents pentylenetetrazole-induced clonic and tonic-clonic seizures without ataxia. ( Gmiro, VE; Serdyuk, SE, 2008) |
| "Male Sprague-Dawley rats injected sc with a single sublethal dose of the organophosphate nerve agent, soman (100 micrograms/kg), had motor limbic seizures within 5-15 min." | 7.68 | Prophylactic and therapeutic efficacy of memantine against seizures produced by soman in the rat. ( Dettbarn, WD; Gupta, RC; McLean, MJ; Wamil, AW, 1992) |
| "Memantine (1-amino-3,5-dimethyladamantane) has previously been shown to attenuate or block chemically or electrically induced seizures in rodents at doses of 5-20 mg/kg i." | 7.68 | High doses of memantine (1-amino-3,5-dimethyladamantane) induce seizures in kindled but not in non-kindled rats. ( Hönack, D; Löscher, W, 1990) |
| "Seizures were evaluated by video-EEG during one hour and scored according to Racine scale." | 5.62 | Effect of Memantine on Pentylenetetrazol-induced Seizures and EEG Profile in Animal Model of Cortical Malformation. ( Cagliari Zenki, K; Calcagnotto, ME; Klippel Zanona, Q; Lazzarotto, G, 2021) |
| "KM rats exhibited increased seizure severity relative to Wistar rats, and the death of KM rats was observed in 2." | 5.38 | [The effect of ionotropic glutamate receptor antagonist on pentylenetetrazole-indused seizures in Krushinsky-Molodkina rats]. ( Kim, KKh; Lavrent'eva, VV; Lukomskaia, NIa; Magazanik, LG; Vataev, SI; Zaĭtsev, AV; Zhabko, EP, 2012) |
| " The present pilot study evaluated the efficacy of memantine, an NMDA receptor antagonist, for the treatment of ERMD in adults with focal-onset seizures." | 5.27 | Does memantine improve memory in subjects with focal-onset epilepsy and memory dysfunction? A randomized, double-blind, placebo-controlled trial. ( Cole, AJ; Garcia, E; Hoch, DB; Leeman-Markowski, BA; Meador, KJ; Moo, LR; Schachter, SC, 2018) |
| " This study compared the anticonvulsant properties of two NMDA receptor channel blockers, memantine and 1-phenylcyclohexylamine (IEM-1921), in a pentylenetetrazole (PTZ) model of seizures in rats and investigated their potencies in preventing PTZ-induced morphological changes in the brain." | 3.81 | N-methyl-D-aspartate receptor channel blockers prevent pentylenetetrazole-induced convulsions and morphological changes in rat brain neurons. ( Kim, KKh; Lavrentyeva, VV; Lukomskaya, NY; Magazanik, LG; Tumanova, NL; Vasilev, DS; Zaitsev, AV; Zhuravin, IA, 2015) |
| "Single intramuscular injection of selective of NMDA receptor blocker memantine in the maximum dose of 20 mg/kg prevented the development of acute generalized tonic-clonic kainate seizures in 60% rats, but did not alleviate clonic kainate seizures and prevented chronic kainate lethality in only 30% rats." | 3.80 | Combined blockade of NMDA and AMPA receptors prevents acute kainate seizures and chronic kainate lethality in rats. ( Gmiro, VE; Serdyuk, SE; Veselkina, OS, 2014) |
| " We found that intracisternal injection of amiloride, an acid-sensing ion channel blocker, dose-dependently reduced cerebral hypoxia-induced neurodegeneration, seizures, and audiogenic myoclonic jerks." | 3.79 | Amiloride but not memantine reduces neurodegeneration, seizures and myoclonic jerks in rats with cardiac arrest-induced global cerebral hypoxia and reperfusion. ( Tai, KK; Truong, DD, 2013) |
| " Following rapid intravenous infusion of equianalgesic bupivacaine, memantine, amantadine and saline (vehicle) in rats, we observed the onset time of seizure, apnea and impending death, and monitored mean arterial blood pressure and heart rate." | 3.78 | Cutaneous analgesia after subcutaneous injection of memantine and amantadine and their systemic toxicity in rats. ( Chen, YC; Chen, YW; Hung, CH; Leung, YM; Shieh, JP; Wang, JJ, 2012) |
| "Intramuscular injection of selective NMDA receptor antagonists memantine and arcaine 4-fold decreased the incidence of pentylenetetrazole-induced generalized tonic-clonic seizures in rats, while the incidence of clonic seizures decreased by 1." | 3.74 | Combined blockade of AMPA and NMDA receptors in the brain of rats prevents pentylenetetrazole-induced clonic and tonic-clonic seizures without ataxia. ( Gmiro, VE; Serdyuk, SE, 2008) |
| "Male Sprague-Dawley rats injected sc with a single sublethal dose of the organophosphate nerve agent, soman (100 micrograms/kg), had motor limbic seizures within 5-15 min." | 3.68 | Prophylactic and therapeutic efficacy of memantine against seizures produced by soman in the rat. ( Dettbarn, WD; Gupta, RC; McLean, MJ; Wamil, AW, 1992) |
| "Memantine (1-amino-3,5-dimethyladamantane) has previously been shown to attenuate or block chemically or electrically induced seizures in rodents at doses of 5-20 mg/kg i." | 3.68 | High doses of memantine (1-amino-3,5-dimethyladamantane) induce seizures in kindled but not in non-kindled rats. ( Hönack, D; Löscher, W, 1990) |
| "Memantine is an N-methyl-D-aspartate receptor antagonist, approved for dementia treatment." | 3.30 | Randomized placebo-controlled crossover trial of memantine in children with epileptic encephalopathy. ( Ayash, TA; Berrahmoune, S; Corriveau, I; Dassi, C; Myers, KA; Osterman, B; Poulin, C; Schiller, K; Sébire, G; Shevell, MI; Simard-Tremblay, E, 2023) |
| "Patients with brain tumors remain at risk for infections from the perioperative period through many months after treatment, and steroids may mask signs of infection." | 2.52 | Medical management of patients with brain tumors. ( Pruitt, AA, 2015) |
| "Epilepsy is considered to result from an imbalance between excitation and inhibition of the central nervous system." | 1.91 | MBD5 regulates NMDA receptor expression and seizures by inhibiting Stat1 transcription. ( Gu, J; Guo, HK; Hu, DM; Huang, R; Ke, PY; Kwan, P; Liu, J; Ma, YL; Tang, FL; Zang, QW; Zhang, H; Zhang, XG; Zhang, ZJ, 2023) |
| "Seizures were evaluated by video-EEG during one hour and scored according to Racine scale." | 1.62 | Effect of Memantine on Pentylenetetrazol-induced Seizures and EEG Profile in Animal Model of Cortical Malformation. ( Cagliari Zenki, K; Calcagnotto, ME; Klippel Zanona, Q; Lazzarotto, G, 2021) |
| "Because both individuals' seizures had proven refractory to conventional antiepileptic medications, the sensitivity of mutant NMDARs to FDA-approved NMDAR antagonists was evaluated." | 1.43 | GRIN2D Recurrent De Novo Dominant Mutation Causes a Severe Epileptic Encephalopathy Treatable with NMDA Receptor Channel Blockers. ( Aizenman, E; Brueckner, F; Chen, W; Chiavacci, R; Elsen, G; Falk, MJ; Hakonarson, H; Hedrich, UB; Hörtnagel, K; Hu, C; Kosobucki, GJ; Kusumoto, H; Lemke, JR; Li, D; Marsh, ED; McCormick, EM; Naase, C; Ortiz-Gonzalez, XR; Schulien, AJ; Tankovic, A; Tian, L; Traynelis, SF; von Stülpnagel-Steinbeis, C; Yuan, H, 2016) |
| "Pretreatment of memantine hydrochloride (10-30 mg/kg." | 1.42 | Memantine delayed N-methyl-D-aspartate -induced convulsions in neonatal rats. ( Chopra, K; Dhir, A, 2015) |
| " Moreover, its use is less toxic and safer." | 1.42 | Comparison of Pharmacological Potency and Safety of Glutamate Blocker IEM-1913 and Memantine. ( Gmiro, VE; Serdyuk, SE; Veselkina, OS, 2015) |
| "KM rats exhibited increased seizure severity relative to Wistar rats, and the death of KM rats was observed in 2." | 1.38 | [The effect of ionotropic glutamate receptor antagonist on pentylenetetrazole-indused seizures in Krushinsky-Molodkina rats]. ( Kim, KKh; Lavrent'eva, VV; Lukomskaia, NIa; Magazanik, LG; Vataev, SI; Zaĭtsev, AV; Zhabko, EP, 2012) |
| "Memantine has been approved to treat moderate to severe Alzheimer disease (AD), which is characterized by cognitive impairment." | 1.37 | Memantine attenuates the impairment of spatial learning and memory of pentylenetetrazol-kindled rats. ( An, LW; Duan, RS; Jia, LJ; Li, ZP; Wang, WP; Zhen, JL, 2011) |
| " These experiments showed that the rats' sleep during the first hour after dosage consisted only of short episodes of superficial slow-wave sleep, and that even this sleep disappeared completely 54." | 1.36 | Effects of memantine on convulsive reactions and the organization of sleep in krushinskii-molodkina rats with an inherited predisposition to audiogenic convulsions. ( Lukomskaya, NY; Magazanik, LG; Oganesyan, GA; Vataev, SI; Zhabko, EP, 2010) |
| "Memantine suppressed generalized tonic-clonic seizures in all age groups; minimal seizures were potentiated." | 1.35 | Different effects of two N-methyl-D-aspartate receptor antagonists on seizures, spontaneous behavior, and motor performance in immature rats. ( Mares, P; Mikulecká, A, 2009) |
| "Memantine was injected i." | 1.35 | [Effects of memantine on convulsive reactions and sleep-waking cycle in Krushinskiĭ-Molodkina strain rats with the inherited predisposition to audiogenic convulsions]. ( Lukomskaia, NIa; Magazanik, LG; Oganesian, GA; Vataev, SI; Zhabko, EP, 2009) |
| "NMDA-induced convulsions were effectively prevented by both mono- and dications, while only dications were effective against kainate convulsions." | 1.32 | The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals. ( Gmiro, VE; Gorbunova, LV; Lukomskaya, NY; Rukoyatkina, NI, 2003) |
| "9 LD50 dose of soman reduced the severity of convulsions and increased survival." | 1.29 | Assessment of primary neuronal culture as a model for soman-induced neurotoxicity and effectiveness of memantine as a neuroprotective drug. ( Deshpande, SS; Filbert, MG; Smith, CD, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (14.71) | 18.2507 |
| 2000's | 7 (20.59) | 29.6817 |
| 2010's | 18 (52.94) | 24.3611 |
| 2020's | 4 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Chidambaram, S | 1 |
| Manokaran, RK | 1 |
| Schiller, K | 1 |
| Berrahmoune, S | 1 |
| Dassi, C | 1 |
| Corriveau, I | 1 |
| Ayash, TA | 1 |
| Osterman, B | 1 |
| Poulin, C | 1 |
| Shevell, MI | 1 |
| Simard-Tremblay, E | 1 |
| Sébire, G | 1 |
| Myers, KA | 1 |
| Tang, FL | 1 |
| Zhang, XG | 1 |
| Ke, PY | 1 |
| Liu, J | 1 |
| Zhang, ZJ | 1 |
| Hu, DM | 1 |
| Gu, J | 1 |
| Zhang, H | 1 |
| Guo, HK | 1 |
| Zang, QW | 1 |
| Huang, R | 1 |
| Ma, YL | 1 |
| Kwan, P | 1 |
| Lazzarotto, G | 1 |
| Klippel Zanona, Q | 1 |
| Cagliari Zenki, K | 1 |
| Calcagnotto, ME | 1 |
| Gmiro, VE | 5 |
| Serdyuk, SE | 4 |
| Veselkina, OS | 3 |
| Leeman-Markowski, BA | 1 |
| Meador, KJ | 1 |
| Moo, LR | 1 |
| Cole, AJ | 1 |
| Hoch, DB | 1 |
| Garcia, E | 1 |
| Schachter, SC | 1 |
| Kim, KKh | 2 |
| Zaĭtsev, AV | 2 |
| Lavrent'eva, VV | 2 |
| Zhabko, EP | 5 |
| Vataev, SI | 4 |
| Lukomskaia, NIa | 4 |
| Magazanik, LG | 6 |
| Tai, KK | 1 |
| Truong, DD | 1 |
| Blecic, S | 1 |
| Rynkowski, M | 1 |
| De Witte, O | 1 |
| Lefranc, F | 1 |
| He, S | 1 |
| Bausch, SB | 1 |
| Dhir, A | 1 |
| Chopra, K | 1 |
| Vasilev, DS | 1 |
| Lukomskaya, NY | 3 |
| Lavrentyeva, VV | 1 |
| Tumanova, NL | 2 |
| Zhuravin, IA | 2 |
| Vasil'ev, DS | 1 |
| Starshinova, LA | 1 |
| Pruitt, AA | 1 |
| Li, D | 1 |
| Yuan, H | 1 |
| Ortiz-Gonzalez, XR | 1 |
| Marsh, ED | 1 |
| Tian, L | 1 |
| McCormick, EM | 1 |
| Kosobucki, GJ | 1 |
| Chen, W | 1 |
| Schulien, AJ | 1 |
| Chiavacci, R | 1 |
| Tankovic, A | 1 |
| Naase, C | 1 |
| Brueckner, F | 1 |
| von Stülpnagel-Steinbeis, C | 1 |
| Hu, C | 1 |
| Kusumoto, H | 1 |
| Hedrich, UB | 1 |
| Elsen, G | 1 |
| Hörtnagel, K | 1 |
| Aizenman, E | 1 |
| Lemke, JR | 1 |
| Hakonarson, H | 1 |
| Traynelis, SF | 1 |
| Falk, MJ | 1 |
| Mares, P | 1 |
| Mikulecká, A | 1 |
| Zaja-Milatovic, S | 1 |
| Gupta, RC | 3 |
| Aschner, M | 2 |
| Milatovic, D | 2 |
| Oganesian, GA | 1 |
| Oganesyan, GA | 1 |
| Jia, LJ | 1 |
| Wang, WP | 1 |
| Li, ZP | 1 |
| Zhen, JL | 1 |
| An, LW | 1 |
| Duan, RS | 1 |
| Chen, YW | 1 |
| Shieh, JP | 1 |
| Chen, YC | 1 |
| Leung, YM | 1 |
| Hung, CH | 1 |
| Wang, JJ | 1 |
| da Cruz, GM | 1 |
| Felipe, CF | 1 |
| Scorza, FA | 1 |
| da Costa, MA | 1 |
| Tavares, AF | 1 |
| Menezes, ML | 1 |
| de Andrade, GM | 1 |
| Leal, LK | 1 |
| Brito, GA | 1 |
| da Graça Naffah-Mazzacoratti, M | 1 |
| Cavalheiro, EA | 1 |
| de Barros Viana, GS | 1 |
| Rukoyatkina, NI | 1 |
| Gorbunova, LV | 1 |
| Peltz, G | 1 |
| Pacific, DM | 1 |
| Noviasky, JA | 1 |
| Shatla, A | 1 |
| Mehalic, T | 1 |
| Milatovic, S | 1 |
| Dettbarn, WD | 2 |
| Deshpande, SS | 1 |
| Smith, CD | 1 |
| Filbert, MG | 1 |
| Hesselink, MB | 1 |
| Smolders, H | 1 |
| Eilbacher, B | 1 |
| De Boer, AG | 1 |
| Breimer, DD | 1 |
| Danysz, W | 1 |
| Urbańska, E | 1 |
| Dziki, M | 1 |
| Czuczwar, SJ | 1 |
| Kleinrok, Z | 1 |
| Turski, WA | 1 |
| McLean, MJ | 1 |
| Wamil, AW | 1 |
| Löscher, W | 1 |
| Hönack, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Double-blind Placebo-controlled Trial of Memantine Hydrochloride for the Treatment of Childhood-onset Epileptic Encephalopathies[NCT03779672] | Phase 4 | 30 participants (Actual) | Interventional | 2019-02-07 | Completed | ||
| Does Memantine Improve Verbal Memory Task Performance in Subjects With Localization-related Epilepsy and Memory Dysfunction? A Randomized, Double-Blind, Placebo-Controlled Trial[NCT01054599] | 29 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability[NCT02002819] | Phase 2 | 34 participants (Actual) | Interventional | 2014-10-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
SRT-CLTR (range 0-72; higher scores indicate better memory), and 7-24 Spatial Memory Test (range 0-35; scores are summed across the 5 learning trials, with higher scores indicating better memory) scores will be assessed across the first (baseline) and third (post-open label memantine) testing sessions. These measures are considered to be scores on a scale, rather than standard units. The hypothesis was that subjects randomized to memantine would demonstrate sustained improvement from baseline, while the placebo group would demonstrate improvements after taking open label memantine (compared to baseline). (NCT01054599)
Timeframe: 26 weeks
| Intervention | scores on a scale (Mean) | |||
|---|---|---|---|---|
| SRT CLTR Baseline | SRT CLTR Post-Open Label | 7-24 Total Learning Baseline | 7-24 Total Learning Post-Open Label | |
| Memantine | 32.67 | 40.33 | 30.33 | 31.67 |
| Sugar Pill | 22.71 | 40.29 | 28.14 | 32.43 |
Change scores from pre- to post-treatment/placebo were calculated for the primary outcome measures, the Selective Reminding Test Continuous Long-Term Retrieval (range 0-72; higher scores indicate better memory) and 7-24 Spatial Recall Test Total Learning (range 0-35; total correct across 5 learning trials are summed, with higher scores indicating better memory) scores. These measures are scores on a scale, rather than representing standard units. (NCT01054599)
Timeframe: 13 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| 7-24 Spatial Recall Tests Learning Change Score | SRT Continuous Long-Term Retrieval Change Score | |
| Memantine | 1.00 | 4.38 |
| Sugar Pill | 1.78 | 8.11 |
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) - The ADAS-cog rating instrument (Rosen et al. 1984) will be used to evaluate the global cognitive functioning. The ADAS-cog is a 70-point scale that includes an assessment of verbal memory, language, orientation, reasoning, and praxis.The score is derived from adding point values from each of its subsections. The higher your score on the ADAS-cog, the better you do. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam (Epileptiform Activity) | -1.0 |
| Placebo (Epileptiform Activity) | 1.5 |
Blood samples intended for Quest Diagnostics LEV and prolactin serum levels (one 6 mL tube) will be processed in the following manner, as outlined in the Quest Diagnostics lab manual. The whole blood will be allowed to clot for 60 minutes and centrifuged at 2200 - 2500 revolutions per minute (RPM) for at least 15 minutes. The resulting serum will be split into 2 cryovials which will be stored at -20°C and immediately shipped for external assessment of LEV and prolactin levels. Prolactin will be assessed via immunoassay. The concentration of LEV in serum will be measured using validated liquid chromatography/tandem mass spectrometry (LC/MS-MS) methods. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | ng/mL (Mean) |
|---|---|
| Levetiracetam | 0.1 |
| Placebo | 0.2 |
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) - The ADAS-cog rating instrument (Rosen et al. 1984) will be used to evaluate the global cognitive functioning. The ADAS-cog is a 70-point scale that includes an assessment of verbal memory, language, orientation, reasoning, and praxis.The score is derived from adding point values from each of its subsections. The higher your score on the ADAS-cog, the better you do. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.2 |
| Placebo | 0.8 |
Alzheimer's Disease Cooperative Study Activities of Daily Living Scale (ADCS-ADL) - The ADCS-ADL rating instrument (Galasko et al. 1997) will be used to evaluate functional capacity. The ADCS-ADL is a caregiver rated questionnaire. Scores on the 24-item ADCS-ADL range from 0 to 78. A higher score indicates less severity while a lower score indicates greater severity. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.4 |
| Placebo | 0.3 |
ADCS-Clinical Global Impression of Change (ADCS-CGIC) - The ADCS-CGIC is a seven-point scale that gives a global rating of change from baseline (Schneider et al. 1997). The baseline and follow up assessments are based on interviews with the subject and the informant. The ADCS-CGIC is a clinician-rated measure of: global severity at baseline scored from 1 (normal, not at all ill) to 7 (among the most extremely ill patients); and global change at follow-up scored from 1 (marked improvement) to 7 (marked worsening), where 4 indicates no change. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 4.0 |
| Placebo | 4.0 |
Neuropsychiatric Inventory (NPI) - The NPI (Cummings et al. 1994) will be used to evaluate the severity of behavioral symptoms. The severity scale has scores ranging from 1 to 3 points (1=mild; 2=moderate; and 3=severe) and the scale for assessing caregiver distress has scores ranging from 0 to 5 points (0=no distress; 1=minimal distress; 2=mild distress; 3=moderate distress; 4=severe distress; and 5=extreme distress). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.8 |
| Placebo | 0.2 |
A 20-minute computer-based virtual navigation test will be used to assess how well a subject can navigate a virtual community to reach a goal destination. The subjects will then be measured on their ability to accurately navigate the virtual community after a period of a few hours. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | correct turns (Mean) |
|---|---|
| No Epileptiform Activity | -6.0 |
| Epileptic Activity | 17.4 |
"Epileptiform activity will be measured using a 1-hr resting magnetoencephalogram/electroencephalogram (M/EEG). M/EEG can detect abnormal epileptiform findings called spikes. The M/EEG will be read by an epileptologist with specialized training to assess whether there are any spikes. If spikes are observed during the M/EEG they will be counted to determine their frequency (e.g., 5 spikes per 1 hour recording). The frequency of spikes will then be compared to baseline values from before beginning the study treatment, using statistical tests to determine if the frequency changed with treatment." (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | Epileptiform events (Mean) |
|---|---|
| Levetiracetam | -0.1 |
| Placebo | -0.2 |
Changes in executive function were measured using the NIH EXAMINER, a 1-hour computer-based battery of various executive function tasks. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. The Examiner assessment consists of the following scales: antisaccade , set shifting , flanker task, dot counting, spatial 1-back, category fluency, and letter fluency. Scores for this task have an indefinite range. Higher scores however do indicate better performance. Scores for this scale were generated using item response theory. For this study, scores with SEs greater than 0.55 were classified as unreliable and excluded from analysis. Composite scores from 2 participants were excluded on this basis.The EXAMINER ranges for the participants in the study were -2.59 to 1.33. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.06 |
| Placebo | -0.14 |
Stroop Test - The Stroop Test (Stroop 1935) will be used to assess executive functions including selective attention, cognitive flexibility and processing speed. Subtasks include Stroop color naming and Stroop interference naming, and each subtask is restricted to 1 minute. The minimum score is 0 and the maximum score is 126. The higher the score the better a participant does. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 1.5 |
| Placebo | -1.4 |
Clinical Dementia Rating Sum of Boxes (CDR-SOB) - The CDR will be used as a global measure of dementia severity (Morris 1993). The CDR consists of questions addressed to the caregiver/informant. The lowest score one can receive is a 0 and the highest is a 3. Score is measured by getting the mean of the individual scores in each category. Lower scores equate to less dementia severity. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.1 |
| Placebo | 0.1 |
Changes in executive function will be measured using the NIH EXAMINER, a 1-hour computer-based battery of various executive function tasks. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. The Examiner assessment consists of the following scales: NIH EXAMINER - antisaccade , NIH EXAMINER - set shifting , NIH EXAMINER - flanker task, NIH EXAMINER - dot counting, NIH EXAMINER - spatial 1-back, NIH EXAMINER - category fluency, and NIH EXAMINER - letter fluency. Scores for this task have an indefinite range. Higher scores however do indicate better performance. Scores for this scale were generated using item response theory (Kramer et al. J Int Neuropsychol Soc. 2014;20(1):11-19. doi:10.1017/S1355617713001094). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| No Epileptiform Activity | -0.01 |
| Epileptiform Activity | 0.22 |
The One Day Fluctuation Assessment Scale will be used to quantitate fluctuations of dementia symptoms (Walker et al. 2000). The One Day Fluctuation Assessment Scale has a score range of 0-21 points,with higher scores indicatingmore fluctuations. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.3 |
| Placebo | -0.4 |
Two standardized methods will be used to quantitate fluctuations of dementia symptoms: The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale (Walker et al. 2000). : The Clinician Assessment of Fluctuation (score range,0-12 points, with higher scores indicating more fluctuations),26 the One Day Fluctuation Assessment Scale (score range,0-21 points, with higher scores indicatingmore fluctuations). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.9 |
| Placebo | 0.1 |
Stroop Test - The Stroop Test (Stroop 1935) will be used to assess executive functions including selective attention, cognitive flexibility and processing speed. Subtasks include Stroop color naming and Stroop interference naming, and each subtask is restricted to 1 minute. The minimum score is 0 and the maximum score is 126. The higher the score the better a participant does. The mean below represents the average change in score between the timepoints for all participants. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam (Epileptiform Activity) | 4.7 |
| Placebo (Epileptiform Activity) | -2.6 |
2 reviews available for memantine and Absence Seizure
| Article | Year |
|---|---|
[Glutamate and malignant gliomas, from epilepsia to biological aggressiveness: therapeutic implications].
Topics: Benzodiazepines; Brain Neoplasms; Cell Death; Cell Movement; Cell Proliferation; Dizocilpine Maleate | 2013 |
Medical management of patients with brain tumors.
Topics: Angiogenesis Inhibitors; Anticonvulsants; Brain Edema; Brain Neoplasms; Cognition Disorders; Dopamin | 2015 |
2 trials available for memantine and Absence Seizure
| Article | Year |
|---|---|
Randomized placebo-controlled crossover trial of memantine in children with epileptic encephalopathy.
Topics: Cross-Over Studies; Double-Blind Method; Epilepsy, Generalized; Excitatory Amino Acid Antagonists; F | 2023 |
Does memantine improve memory in subjects with focal-onset epilepsy and memory dysfunction? A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Attention; Cognition; Double-Blind Method; Epilepsies, Partial; Excitatory Amino Acid Antagon | 2018 |
30 other studies available for memantine and Absence Seizure
| Article | Year |
|---|---|
Favorable Response to "Memantine" in a Child with GRIN2B Epileptic Encephalopathy.
Topics: Child; Humans; Infant; Male; Memantine; Mutation; Receptors, N-Methyl-D-Aspartate; Seizures; Spasms, | 2022 |
MBD5 regulates NMDA receptor expression and seizures by inhibiting Stat1 transcription.
Topics: Animals; Epilepsy; Memantine; Mice; Receptors, N-Methyl-D-Aspartate; Seizures; Signal Transduction; | 2023 |
Effect of Memantine on Pentylenetetrazol-induced Seizures and EEG Profile in Animal Model of Cortical Malformation.
Topics: Animals; Disease Models, Animal; Electroencephalography; Male; Memantine; Pentylenetetrazole; Rats; | 2021 |
[COMPARISON OF CHRONIC ANTICONVULSANT ACTIVITY AND SAFETY OF IEM-2062, SODIUM VALPROATE AND ME-MANTINE IN THE PENTYLENETETRAZOL KINDLING MODEL IN RATS].
Topics: Administration, Oral; Animals; Anticonvulsants; Convulsants; Cyclohexanes; Cyclohexylamines; Drug Ad | 2017 |
[The effect of ionotropic glutamate receptor antagonist on pentylenetetrazole-indused seizures in Krushinsky-Molodkina rats].
Topics: Animals; Anticonvulsants; Cyclohexylamines; Epilepsy, Reflex; Excitatory Amino Acid Antagonists; Fem | 2012 |
Amiloride but not memantine reduces neurodegeneration, seizures and myoclonic jerks in rats with cardiac arrest-induced global cerebral hypoxia and reperfusion.
Topics: Acid Sensing Ion Channels; Amiloride; Animals; Brain Injuries; Heart Arrest; Hypoxia, Brain; Male; M | 2013 |
Synaptic plasticity in glutamatergic and GABAergic neurotransmission following chronic memantine treatment in an in vitro model of limbic epileptogenesis.
Topics: Animals; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Hippocampus; Mem | 2014 |
Combined blockade of NMDA and AMPA receptors prevents acute kainate seizures and chronic kainate lethality in rats.
Topics: Adamantane; Amines; Animals; Anticonvulsants; Convulsants; Dose-Response Relationship, Drug; Excitat | 2014 |
Memantine delayed N-methyl-D-aspartate -induced convulsions in neonatal rats.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Female; Male; Memantine; N-Methylaspartate; Rats; | 2015 |
N-methyl-D-aspartate receptor channel blockers prevent pentylenetetrazole-induced convulsions and morphological changes in rat brain neurons.
Topics: Animals; Brain; Caspase 3; Cell Shape; Cyclohexylamines; Excitatory Amino Acid Antagonists; Male; Me | 2015 |
[The ability of NMDA glutamate receptor blockers to prevent a pentylenetetrazole kindling in mice and morphological changes in the hippocampus].
Topics: Animals; DNA-Binding Proteins; Hippocampus; Kindling, Neurologic; Memantine; Mice; Nerve Tissue Prot | 2013 |
Comparison of Pharmacological Potency and Safety of Glutamate Blocker IEM-1913 and Memantine.
Topics: Analgesics; Animals; Anticonvulsants; Antidepressive Agents; Antiparkinson Agents; Bridged-Ring Comp | 2015 |
GRIN2D Recurrent De Novo Dominant Mutation Causes a Severe Epileptic Encephalopathy Treatable with NMDA Receptor Channel Blockers.
Topics: Amino Acid Sequence; Base Sequence; Cell Death; Child; Dendrites; DNA Mutational Analysis; Electroen | 2016 |
Different effects of two N-methyl-D-aspartate receptor antagonists on seizures, spontaneous behavior, and motor performance in immature rats.
Topics: Animals; Anticonvulsants; Behavior, Animal; Convulsants; Dose-Response Relationship, Drug; Epilepsy, | 2009 |
Combined blockade of AMPA and NMDA receptors in the brain of rats prevents pentylenetetrazole-induced clonic and tonic-clonic seizures without ataxia.
Topics: Animals; Ataxia; Biguanides; Drug Synergism; Drug Therapy, Combination; Epilepsy, Tonic-Clonic; Male | 2008 |
Protection of DFP-induced oxidative damage and neurodegeneration by antioxidants and NMDA receptor antagonist.
Topics: Animals; Antioxidants; Biomarkers; Brain; Cholinesterase Inhibitors; Cyclic N-Oxides; Disease Models | 2009 |
[Effects of memantine on convulsive reactions and sleep-waking cycle in Krushinskiĭ-Molodkina strain rats with the inherited predisposition to audiogenic convulsions].
Topics: Acoustic Stimulation; Animals; Anticonvulsants; Electroencephalography; Memantine; Rats; Receptors, | 2009 |
Effects of memantine on convulsive reactions and the organization of sleep in krushinskii-molodkina rats with an inherited predisposition to audiogenic convulsions.
Topics: Acoustic Stimulation; Animals; Anticonvulsants; Electroencephalography; Memantine; Rats; Receptors, | 2010 |
Memantine attenuates the impairment of spatial learning and memory of pentylenetetrazol-kindled rats.
Topics: Animals; Behavior, Animal; Convulsants; Excitatory Amino Acid Antagonists; Kindling, Neurologic; Lea | 2011 |
[Effects of ionotropic glutamate receptor channel blockers on the development of audiogenic seizures in Krushinski-Molodkina rats].
Topics: Acoustic Stimulation; Adamantane; Animals; Cyclohexylamines; Diamines; Drug Administration Schedule; | 2012 |
Cutaneous analgesia after subcutaneous injection of memantine and amantadine and their systemic toxicity in rats.
Topics: Amantadine; Analgesia; Analgesics, Non-Narcotic; Anesthetics, Local; Animals; Apnea; Behavior, Anima | 2012 |
Piperine decreases pilocarpine-induced convulsions by GABAergic mechanisms.
Topics: Alkaloids; Amino Acids; Animals; Anticonvulsants; Antioxidants; Atropine; Benzodioxoles; Biogenic Mo | 2013 |
The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals.
Topics: Animals; Ataxia; Behavior, Animal; Catalepsy; Diamines; Disease Models, Animal; Dizocilpine Maleate; | 2003 |
Seizures associated with memantine use.
Topics: Aged; Benzodiazepines; Dopamine Agents; Drug Synergism; Female; Humans; Memantine; Neuroprotective A | 2005 |
Neuronal oxidative injury and dendritic damage induced by carbofuran: protection by memantine.
Topics: Acetylcholinesterase; Animals; Carbofuran; Cholinesterase Inhibitors; Citrulline; Dendritic Cells; L | 2007 |
Assessment of primary neuronal culture as a model for soman-induced neurotoxicity and effectiveness of memantine as a neuroprotective drug.
Topics: Acetylcholine; Animals; Cell Death; Cell Survival; Cells, Cultured; Cerebral Cortex; Cholinesterase | 1995 |
The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-D-aspartate receptor antagonists acting at the glycine(B)-site: microdialysis and maximum electroshock seizures studies.
Topics: Animals; Anion Transport Proteins; Biological Transport; Carrier Proteins; Drug Interactions; Electr | 1999 |
Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Avoidance Learning; Drug Synergism; Electroshock; Ma | 1992 |
Prophylactic and therapeutic efficacy of memantine against seizures produced by soman in the rat.
Topics: Animals; Atropine; Brain; Cells, Cultured; Cholinesterase Inhibitors; Male; Memantine; Mice; Neurons | 1992 |
High doses of memantine (1-amino-3,5-dimethyladamantane) induce seizures in kindled but not in non-kindled rats.
Topics: Amantadine; Amygdala; Animals; Dose-Response Relationship, Drug; Electric Stimulation; Female; Kindl | 1990 |